Sarepta Therapeutics
SRPT
389 hedge funds and large institutions have $9.51B invested in Sarepta Therapeutics in 2019 Q4 according to their latest regulatory filings, with 104 funds opening new positions, 117 increasing their positions, 110 reducing their positions, and 48 closing their positions.
117% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 48
72% more capital invested
Capital invested by funds: $5.52B → $9.51B (+$3.98B)
47% more call options, than puts
Call options by funds: $573M | Put options by funds: $391M
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
14% more funds holding
Funds holding: 340 → 389 (+49)
6% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 110
0.42% less ownership
Funds ownership: 99.26% → 98.84% (-0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$243M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$95.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$87.3M |
| 4 |
JP Morgan Chase
New York
|
+$84.2M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
+$61.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$186M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$70.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$64.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$47.1M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$46.9M |
SRPT Hedge Fund Activity: Q4 2019 in Review
389 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2019, worth a combined $9.51B — up 72% from $5.52B a quarter earlier.
Buyers outnumbered sellers: 104 funds opened new SRPT positions and 48 closed out — a net gain of 56 holders — while 117 added to existing stakes and 110 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $243M. The largest seller was Fidelity International, cutting an estimated $186M.
- 389 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2019, up from 340 in Q3 2019.
- Funds reported $9.51B of Sarepta Therapeutics stock for Q4 2019, up 72% quarter-over-quarter.
- 104 funds opened new Sarepta Therapeutics positions in Q4 2019 and 48 closed out, a net change of +56 holders.
- The largest Sarepta Therapeutics buyer in Q4 2019 was Capital Research Global Investors, an estimated $243M added.
- The largest Sarepta Therapeutics seller in Q4 2019 was Fidelity International, an estimated $186M sold.
Based on aggregated 13F filings for Q4 2019.